JunHe assisted Viva Biotech on the deal. Viva Biotech completed the acquisition ratio of Viva had increased to 80% and the total consideration to RMB 2.56…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
